• Cosgrove N*, Varešlija D*, Keelan S, Elangovan A, Atkinson JM, Cocchiglia S, Bane FT, Singh V, Furney S, Hu C, Carter JM, Hart SN, Yadav S, Goetz MP, Hill ADK, Oesterreich S, Lee AV, Couch FJ*, Young LS*. Mapping molecular subtype specific alterations in breast cancer brain metastases identifies clinically relevant vulnerabilities. Nat Commun. 2022 Jan 26;13(1):514. doi: 10.1038/s41467-022-27987-5.PMID: 35082299 Senior shared
  • Zhu L, Retana D………,Young LS, Varešlija D, Cosgrove N, Couch FJ, Cussó L, Desco M, Mouron S, Quintela-Fandino M, Weller M, Pastor J, Valiente M.A clinically compatible drug-screening platform based on organotypic cultures identifies vulnerabilities to prevent and treat brain metastasis. EMBO Mol Med. 2022 Mar 7;14(3):e14552. doi: 10.15252/emmm.202114552. Epub 2022 Feb 17.PMID: 35174975
  • Monteiro C, Miarka L, ……., Hegarty A, Keelan S, Varešlija D, Young LS, Mohme M, Goy Y, Wikman H, Fernández-Alén J, Blasco G, Alcázar L, Cabañuz C, Grivennikov SI, Ianus A, Shemesh N, Faria CC, Lee R, Lorigan P, Le Rhun E, Weller M, Soffietti R, Bertero L, Ricardi U, Bosch-Barrera J, Sais E, Teixidor E, Hernández-Martínez A, Calvo A, Aristu J, Martin SM, Gonzalez A, Adler O, Erez N; RENACER, Valiente M.Stratification of radiosensitive brain metastases based on an actionable S100A9/RAGE resistance mechanism. Nat Med. 2022 Apr;28(4):752-765. doi: 10.1038/s41591-022-01749-8. Epub 2022 Apr 11.PMID: 35411077





Selected Older Publications

  • Charmsaz S, Hughes É, Bane FT, Tibbitts P, McIlroy M, Byrne C, Cocchiglia S, McBryan J, Hennessy BT, Dwyer RM, Kerin MJ, Hill AD, Young LS. S100β as a serum marker in endocrine resistant breast cancer. BMC Med. 2017 Apr 12;15(1):79. doi: 10.1186/s12916-017-0836-2
  • Varešlija D, McBryan J, Fagan A, Redmond AM, Hao Y, Sims AH, Turnbull A, Dixon JM, Ó Gaora P, Hudson L, Purcell S, Hill AD, Young LS. Adaptation to AI Therapy in Breast Cancer Can Induce Dynamic Alterations in ER Activity Resulting in Estrogen-Independent Metastatic Tumors. Clin Cancer Res. 2016 Jun 1;22(11):2765-77.
  • McBryan J, Fagan A, McCartan D, Bane FT, Varešlija D, Cocchiglia S, Byrne C, Bolger J, McIlroy M, Hudson L, Tibbitts P, Gaora PÓ, Hill AD, Young LS. Transcriptomic Profiling of Sequential Tumors from Breast Cancer Patients Provides a Global View of Metastatic Expression Changes Following Endocrine Therapy. Clin Cancer Res. 2015 Dec 1;21(23):5371-9
  • Redmond AM, Byrne C, Bane FT, Brown GD, Tibbitts P, O’Brien K, Hill AD, Carroll JS, Young LS. Genomic interaction between ER and HMGB2 identifies DDX18 as a novel driver of endocrine resistance in breast cancer cells. Oncogene. 2015 Jul;34(29):3871-80.
  • McCartan D, Bolger J, Fagan A, Byrne C, Hao Y, Qin L, McIlroy M, Xu J, Hill A, O Gaora P, Young LS. Global characterization of the SRC-1 transcriptome identifies ADAM22 as an ER-independent mediator of endocrine resistant breast cancer. Cancer Res. 2012 Jan 1;72(1):220-9. PMID:22072566
  • McBryan J, Theissen SM, Byrne C, Hughes E, Cocchiglia S, Sande S, O’Hara J, Tibbitts PS, Hill A, Young LS. Metastatic progression with resistance to aromatase inhibitors is driven by the steroid receptor coactivator SRC-1. Cancer Res. 2012 Jan 15;72(2):548-59 PMID:22108824
  • McIlroy M, McCartan D, Early S, O Gaora P, Pennington S, Hill AD, Young LS. Interaction of developmental transcription factor HOX11 with steroid receptor coactivator SRC-1 mediates resistance to endocrine therapy in breast cancer. Cancer Res. 2010 Feb 15;70(4):1585-94. PMID: 20145129
  • Redmond AM, Bane F, Stafford AT, Crotty TB, McIlroy M, Hill AD, Young LS. Coassociation of ER and p160 proteins predicts resistance to endocrine treatment; SRC-1 is an independent predictor of breast cancer recurrence. Clinical Cancer Research, 2009 Mar 15;15(6):2098-106. PMID: 19276281